- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Lilly Slaps $8,000-Per-Treatment-Cycle Price Tag On Lung Cancer Drug
December 21, 2015.
FDA News reports that Eli Lilly has put a premium price tag on its new lung cancer drug Portrazza: $8,000 per treatment cycle.
FDA approved the drug, which is indicated for patients with squamous non-small cell lung cancer, in late November.
Lilly spokeswoman Carla Cox said the average patient will require six courses of treatment, which at $8,000 for each cycle works out to $48,000. But, FDA News adds, "she stressed that very few patients would ever pay this price, due to insurance coverage, medical assistance programs and price negotiations between industry and insurers".
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
